☰

Gregory Riggins - Publications

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Oncology, Pathology, Neuroscience Biology
Tree Info Grants Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Yamashita AS, da Costa Rosa M, Stumpo V, Rais R, Slusher BS, Riggins GJ. The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. Neuro-Oncology Advances. 3: vdaa149. PMID 33681764 DOI: 10.1093/noajnl/vdaa149  0.378
2018 Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ. Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide. Neuro-Oncology. PMID 30184215 DOI: 10.1093/Neuonc/Noy146  0.37
2018 Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, et al. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications. 9: 1057. PMID 29535300 DOI: 10.1038/S41467-018-03476-6  0.312
2018 Bautista W, Abu-Asab M, Amable L, Ross L, Riggins G, Kozlov S. 19 Autophagy related metals in IDH1 mutant glioma: Chloroquine and TMZ as a potential novel strategy to treat IDH1 mt gliomas Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 45: S3-S4. DOI: 10.1017/cjn.2018.261  0.313
2015 Borodovsky A, Meeker AK, Kirkness EF, Zhao Q, Eberhart CG, Gallia GL, Riggins GJ. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. Journal of Neuro-Oncology. 121: 479-87. PMID 25471051 DOI: 10.1007/S11060-014-1672-2  0.394
2014 Borodovsky A, Riggins G. Et-08Demethylating Therapy Induces Differentation And Therapeutic Response In Idh1 Mutant Malignant Gliomas. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou255.8  0.488
2014 Bai R, Staedtke V, Rudin C, Bunz F, Riggins G. ET-04 * MEBENDAZOLE IS EFFICACIOUS IN DIVERSE MEDULLOBLASTOMA TUMOR MODELS AND INHIBITS TUMOR ANGIOGENESIS Neuro-Oncology. 16: v79-v79. DOI: 10.1093/Neuonc/Nou255.4  0.34
2013 Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 4: 1729-36. PMID 24077826 DOI: 10.18632/Oncotarget.1412  0.425
2013 Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 4: 1737-47. PMID 24077805 DOI: 10.18632/Oncotarget.1408  0.358
2013 Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, ... ... Riggins GJ, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1093/Neuonc/Nou206.18  0.33
2012 Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, ... ... Riggins GJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3: 709-22. PMID 22869205 DOI: 10.18632/Oncotarget.588  0.342
2012 Borodovsky A, Seltzer MJ, Riggins GJ. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Current Opinion in Oncology. 24: 83-9. PMID 22080945 DOI: 10.1097/Cco.0B013E32834D816A  0.592
2012 Baia GS, Woodworth G, Ford E, Riggins G. Abstract 2759: Targeting NF2 deficient meningiomas with combinations of small molecule inhibitors and radiation Cancer Research. 72: 2759-2759. DOI: 10.1158/1538-7445.Am2012-2759  0.346
2011 Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (New York, N.Y.). 333: 1453-5. PMID 21817013 DOI: 10.1126/Science.1210557  0.422
2011 Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, ... ... Riggins GJ, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science (New York, N.Y.). 333: 425. PMID 21719641 DOI: 10.1126/Science.1207313  0.322
2010 Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Research. 70: 8981-7. PMID 21045145 DOI: 10.1158/0008-5472.Can-10-1666  0.591
2009 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 360: 765-73. PMID 19228619 DOI: 10.1056/Nejmoa0808710  0.376
2007 Trembath DG, Lal A, Kroll DJ, Oberlies NH, Riggins GJ. A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Molecular Cancer. 6: 30. PMID 17437646 DOI: 10.1186/1476-4598-6-30  0.359
2006 Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS, Riggins GJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Molecular Cancer Research : McR. 4: 709-14. PMID 17050665 DOI: 10.1158/1541-7786.Mcr-06-0172  0.375
2006 Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, ... ... Riggins G, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Research. 66: 3987-91. PMID 16618716 DOI: 10.1158/0008-5472.Can-06-0127  0.412
2004 Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A, Riggins G, Anderson S, Vredenburgh J, Proia A, Harris LN. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4083-8. PMID 15217943 DOI: 10.1158/1078-0432.Ccr-03-0695  0.313
2004 Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (New York, N.Y.). 304: 1164-6. PMID 15155950 DOI: 10.1126/Science.1096096  0.355
2002 Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, ... ... Riggins GJ, et al. Mutations of the BRAF gene in human cancer. Nature. 417: 949-54. PMID 12068308 DOI: 10.1038/Nature00766  0.334
1999 Wind Nd, Dekker M, Claij N, Jansen L, Klink Yv, Radman M, Riggins G, Valk Mvd, Wout Kv, Riele Ht. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions Nature Genetics. 23: 359-362. PMID 10545954 DOI: 10.1038/15544  0.302
1994 Riggins GJ, Zhang F, Warren ST. Lack of imprinting of BCR Nature Genetics. 6: 226. PMID 8012382 DOI: 10.1038/Ng0394-226  0.441
1994 Riggins GJ, Sherman SL, Phillips CN, Stock W, Westbrook CA, Warren ST. CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome. Genes, Chromosomes & Cancer. 9: 141-4. PMID 7513545 DOI: 10.1002/Gcc.2870090211  0.461
1993 Riggins GJ, Lokey LK, Chastain JL, Leiner HA, Sherman SL, Wilkinson KD, Warren ST. Erratum: Corrigendum: Human genes containing polymorphic trinucleotide repeats Nature Genetics. 3: 273-273. DOI: 10.1038/Ng0393-273B  0.44
1992 Riggins GJ, Sherman SL, Oostra BA, Sutcliffe JS, Feitell D, Nelson DL, Van Oost BA, Smits APT, Ramos FJ, Pfendner E, Kuhl DPA, Caskey CT, Warren ST. Characterization of a highly polymorphic dinucleotide repeat 150 kb proximal to the fragile X site American Journal of Medical Genetics. 43: 237-243. PMID 1605197 DOI: 10.1002/Ajmg.1320430138  0.597
1992 Riggins GJ, Lokey LK, Chastain JL, Leiner HA, Sherman SL, Wilkinson KD, Warren ST. Human genes containing polymorphic trinucleotide repeats Nature Genetics. 2: 186-191. PMID 1345166 DOI: 10.1038/Ng1192-186  0.49
1992 Riggins GJ, Lokey LK, Warren ST. CCG repeat polymorphism at the c-Ha-ras oncogene locus Human Molecular Genetics. 1: 775. PMID 1302617 DOI: 10.1093/Hmg/1.9.775  0.428
Show low-probability matches.